Miglustat is a substrate reduction therapy indicated for the oral treatment of patients with Gaucher disease.1 The mechanism of action of miglustat is presented in Figure 1. For further information on miglustat, please consult your local prescribing information.
Mechanism of action of miglustat1,2
C-ANPROM/INT//7568; Date of preparation: September 2020
- Accord-Healthcare Ltd. Zavesca® EU Summary of Product Characteristics. Last updated July 2019.
- Stirnemann J, Belmatoug N, Camou F, et al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci 2017; 18: 441.